Prostate Cancer Screening Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
293 Pages
November 2023
Region: Global
Fairfield Market Research
ID: 5908979

Prostate cancer is a condition that affects the male population, originating in the prostate gland within the male reproductive system. It is one of the most commonly diagnosed cancers in men, with a higher likelihood of diagnosis in individuals over the age of 50. While prostate cancer is not infectious or contagious, risk factors such as family history, age, diet, and lifestyle play a role.

Prostate cancer often lacks early symptoms, making early detection crucial. Various tests are available for diagnosing prostate cancer, with most cases being adenocarcinomas, originating from prostate cells. Different types of prostate cancer include sarcomas, small cell carcinomas, neuroendocrine tumors, and transitional cell carcinomas. Prostate cancer screening involves staging and grading, where staging determines the extent of the cancer, and grading categorizes the type of cancer as low, intermediate, or high grade.

Driving Factors for the Prostate Cancer Screening Market:

The Prostate Cancer Screening Market is experiencing growth driven by factors such as increased patient awareness about healthcare concerns, the acceptance of serum-based marker testing for diagnosis, ongoing research for cancer detection, and government initiatives and public awareness campaigns. Companies are investing in innovative products for early prostate cancer detection to reduce the number of deaths.

Challenges and Restraints:

However, challenges exist in the form of unnecessary repeated biopsies and screening procedures, side effects of surgery, risk of over-diagnosis and overtreatment, and the cost of prostate cancer screening tests.

Regional Insights:

North America: Leading in the prostate cancer screening market, North America's growth is fueled by a high incidence of prostate cancer, rigorous regulatory oversight, technological advancements, and increased funding.
Europe: Following North America, European countries are also expected to show steady growth in the market.
Asia-Pacific: This region is emerging as a growing player in prostate cancer screening, driven by government initiatives, rising healthcare concerns, and an improving healthcare scenario.

Key Players:

The prostate cancer screening market is home to numerous players, including Abbott Laboratories, Bayer AG, bioMérieux SA, General Electric Company, Roche Diagnostics, and more. Regional players also have a significant market share in emerging countries.

The global prostate cancer screening market is on the rise, driven by awareness campaigns and technological advancements. Despite challenges, the market is poised for growth, with North America maintaining a leading position.

Prostate Cancer Screening Market: Segmentation:

Various Tests:

Physical Exam
Laboratory Tests

o Prostate-Specific Antigen (PSA) Blood Test:

Imaging Tests

o Transrectal ultrasound (TRUS)

o Bone scan:

o Computed tomography (CT) scan:

o Magnetic resonance imaging (MRI)

o Lymph node biopsy:

o Positron Emission Tomography:

Gleason Score
TNM Score
Genetic Tests
Digital Rectal Exam (DRE)
Biopsy

o Fine-Needle Aspiration:

End User Industry:

Hospitals
Clinics
Research Labs
Cancer Institutes
Diagnostic Centers
Others

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Prostate Cancer Screening Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Prostate Cancer Screening Market Outlook, 2018 - 2031

3.1. Global Prostate Cancer Screening Market Outlook, by Various Tests, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Physical Exam
3.1.1.2. Laboratory Tests
3.1.1.2.1. Prostate-Specific Antigen (PSA) Blood Test
3.1.1.3. Imaging Tests
3.1.1.3.1. Transrectal ultrasound (TRUS)
3.1.1.3.2. Bone scan
3.1.1.3.3. Computed tomography (CT) scan
3.1.1.3.4. Magnetic resonance imaging (MRI)
3.1.1.3.5. Lymph node biopsy
3.1.1.3.6. Positron Emission Tomography
3.1.1.4. Gleason Score
3.1.1.5. TNM Score
3.1.1.6. Genetic Tests
3.1.1.7. Digital Rectal Exam (DRE)
3.1.1.8. Biopsy
3.1.1.8.1. Fine-Needle Aspiration
3.2. Global Prostate Cancer Screening Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Hospitals
3.2.1.2. Clinics
3.2.1.3. Research Labs
3.2.1.4. Cancer Institutes
3.2.1.5. Diagnostic Centers
3.2.1.6. Others
3.3. Global Prostate Cancer Screening Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa

4. North America Prostate Cancer Screening Market Outlook, 2018 - 2031

4.1. North America Prostate Cancer Screening Market Outlook, by Various Tests, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Physical Exam
4.1.1.2. Laboratory Tests
4.1.1.2.1. Prostate-Specific Antigen (PSA) Blood Test
4.1.1.3. Imaging Tests
4.1.1.3.1. Transrectal ultrasound (TRUS)
4.1.1.3.2. Bone scan
4.1.1.3.3. Computed tomography (CT) scan
4.1.1.3.4. Magnetic resonance imaging (MRI)
4.1.1.3.5. Lymph node biopsy
4.1.1.3.6. Positron Emission Tomography
4.1.1.4. Gleason Score
4.1.1.5. TNM Score
4.1.1.6. Genetic Tests
4.1.1.7. Digital Rectal Exam (DRE)
4.1.1.8. Biopsy
4.1.1.8.1. Fine-Needle Aspiration
4.2. North America Prostate Cancer Screening Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Hospitals
4.2.1.2. Clinics
4.2.1.3. Research Labs
4.2.1.4. Cancer Institutes
4.2.1.5. Diagnostic Centers
4.2.1.6. Others
4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Prostate Cancer Screening Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. U.S. Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
4.3.1.2. U.S. Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
4.3.1.3. Canada Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
4.3.1.4. Canada Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Prostate Cancer Screening Market Outlook, 2018 - 2031

5.1. Europe Prostate Cancer Screening Market Outlook, by Various Tests, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Physical Exam
5.1.1.2. Laboratory Tests
5.1.1.2.1. Prostate-Specific Antigen (PSA) Blood Test
5.1.1.3. Imaging Tests
5.1.1.3.1. Transrectal ultrasound (TRUS)
5.1.1.3.2. Bone scan
5.1.1.3.3. Computed tomography (CT) scan
5.1.1.3.4. Magnetic resonance imaging (MRI)
5.1.1.3.5. Lymph node biopsy
5.1.1.3.6. Positron Emission Tomography
5.1.1.4. Gleason Score
5.1.1.5. TNM Score
5.1.1.6. Genetic Tests
5.1.1.7. Digital Rectal Exam (DRE)
5.1.1.8. Biopsy
5.1.1.8.1. Fine-Needle Aspiration
5.2. Europe Prostate Cancer Screening Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Hospitals
5.2.1.2. Clinics
5.2.1.3. Research Labs
5.2.1.4. Cancer Institutes
5.2.1.5. Diagnostic Centers
5.2.1.6. Others
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Prostate Cancer Screening Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Germany Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
5.3.1.2. Germany Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
5.3.1.3. U.K. Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
5.3.1.4. U.K. Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
5.3.1.5. France Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
5.3.1.6. France Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
5.3.1.7. Italy Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
5.3.1.8. Italy Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
5.3.1.9. Turkey Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
5.3.1.10. Turkey Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
5.3.1.11. Russia Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
5.3.1.12. Russia Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
5.3.1.13. Rest of Europe Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
5.3.1.14. Rest of Europe Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Prostate Cancer Screening Market Outlook, 2018 - 2031

6.1. Asia Pacific Prostate Cancer Screening Market Outlook, by Various Tests, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Physical Exam
6.1.1.2. Laboratory Tests
6.1.1.2.1. Prostate-Specific Antigen (PSA) Blood Test
6.1.1.3. Imaging Tests
6.1.1.3.1. Transrectal ultrasound (TRUS)
6.1.1.3.2. Bone scan
6.1.1.3.3. Computed tomography (CT) scan
6.1.1.3.4. Magnetic resonance imaging (MRI)
6.1.1.3.5. Lymph node biopsy
6.1.1.3.6. Positron Emission Tomography
6.1.1.4. Gleason Score
6.1.1.5. TNM Score
6.1.1.6. Genetic Tests
6.1.1.7. Digital Rectal Exam (DRE)
6.1.1.8. Biopsy
6.1.1.8.1. Fine-Needle Aspiration
6.2. Asia Pacific Prostate Cancer Screening Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Hospitals
6.2.1.2. Clinics
6.2.1.3. Research Labs
6.2.1.4. Cancer Institutes
6.2.1.5. Diagnostic Centers
6.2.1.6. Others
6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Prostate Cancer Screening Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. China Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
6.3.1.2. China Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
6.3.1.3. Japan Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
6.3.1.4. Japan Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
6.3.1.5. South Korea Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
6.3.1.6. South Korea Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
6.3.1.7. India Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
6.3.1.8. India Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
6.3.1.9. Southeast Asia Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
6.3.1.10. Southeast Asia Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
6.3.1.11. Rest of Asia Pacific Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
6.3.1.12. Rest of Asia Pacific Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Prostate Cancer Screening Market Outlook, 2018 - 2031

7.1. Latin America Prostate Cancer Screening Market Outlook, by Various Tests, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Physical Exam
7.1.1.2. Laboratory Tests
7.1.1.2.1. Prostate-Specific Antigen (PSA) Blood Test
7.1.1.3. Imaging Tests
7.1.1.3.1. Transrectal ultrasound (TRUS)
7.1.1.3.2. Bone scan
7.1.1.3.3. Computed tomography (CT) scan
7.1.1.3.4. Magnetic resonance imaging (MRI)
7.1.1.3.5. Lymph node biopsy
7.1.1.3.6. Positron Emission Tomography
7.1.1.4. Gleason Score
7.1.1.5. TNM Score
7.1.1.6. Genetic Tests
7.1.1.7. Digital Rectal Exam (DRE)
7.1.1.8. Biopsy
7.1.1.8.1. Fine-Needle Aspiration
7.2. Latin America Prostate Cancer Screening Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
7.2.1.1. Hospitals
7.2.1.2. Clinics
7.2.1.3. Research Labs
7.2.1.4. Cancer Institutes
7.2.1.5. Diagnostic Centers
7.2.1.6. Others
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Prostate Cancer Screening Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Brazil Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
7.3.1.2. Brazil Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
7.3.1.3. Mexico Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
7.3.1.4. Mexico Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
7.3.1.5. Argentina Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
7.3.1.6. Argentina Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
7.3.1.7. Rest of Latin America Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
7.3.1.8. Rest of Latin America Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Prostate Cancer Screening Market Outlook, 2018 - 2031

8.1. Middle East & Africa Prostate Cancer Screening Market Outlook, by Various Tests, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Physical Exam
8.1.1.2. Laboratory Tests
8.1.1.2.1. Prostate-Specific Antigen (PSA) Blood Test
8.1.1.3. Imaging Tests
8.1.1.3.1. Transrectal ultrasound (TRUS)
8.1.1.3.2. Bone scan
8.1.1.3.3. Computed tomography (CT) scan
8.1.1.3.4. Magnetic resonance imaging (MRI)
8.1.1.3.5. Lymph node biopsy
8.1.1.3.6. Positron Emission Tomography
8.1.1.4. Gleason Score
8.1.1.5. TNM Score
8.1.1.6. Genetic Tests
8.1.1.7. Digital Rectal Exam (DRE)
8.1.1.8. Biopsy
8.1.1.8.1. Fine-Needle Aspiration
8.2. Middle East & Africa Prostate Cancer Screening Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Hospitals
8.2.1.2. Clinics
8.2.1.3. Research Labs
8.2.1.4. Cancer Institutes
8.2.1.5. Diagnostic Centers
8.2.1.6. Others
8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Prostate Cancer Screening Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. GCC Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
8.3.1.2. GCC Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
8.3.1.3. South Africa Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
8.3.1.4. South Africa Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
8.3.1.5. Egypt Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
8.3.1.6. Egypt Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
8.3.1.7. Nigeria Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
8.3.1.8. Nigeria Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
8.3.1.9. Rest of Middle East & Africa Prostate Cancer Screening Market by Various Tests, Value (US$ Bn), 2018 - 2031
8.3.1.10. Rest of Middle East & Africa Prostate Cancer Screening Market by End User, Value (US$ Bn), 2018 - 2031
8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Manufacturer vs by End User Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1.1. Abbott Laboratories
9.4.1.1.1. Company Overview
9.4.1.1.2. Product Portfolio
9.4.1.1.3. Financial Overview
9.4.1.1.4. Business Strategies and Development
9.4.1.2. Almac Group
9.4.1.2.1. Company Overview
9.4.1.2.2. Product Portfolio
9.4.1.2.3. Financial Overview
9.4.1.2.4. Business Strategies and Development
9.4.1.3. Bayer AG
9.4.1.3.1. Company Overview
9.4.1.3.2. Product Portfolio
9.4.1.3.3. Financial Overview
9.4.1.3.4. Business Strategies and Development
9.4.1.4. Beckman Coulter, Inc.
9.4.1.4.1. Company Overview
9.4.1.4.2. Product Portfolio
9.4.1.4.3. Financial Overview
9.4.1.4.4. Business Strategies and Development
9.4.1.5. bioMérieux SA
9.4.1.5.1. Company Overview
9.4.1.5.2. Product Portfolio
9.4.1.5.3. Financial Overview
9.4.1.5.4. Business Strategies and Development
9.4.1.6. General Electric Company
9.4.1.6.1. Company Overview
9.4.1.6.2. Product Portfolio
9.4.1.6.3. Financial Overview
9.4.1.6.4. Business Strategies and Development
9.4.1.7. Genomic Health
9.4.1.7.1. Company Overview
9.4.1.7.2. Product Portfolio
9.4.1.7.3. Financial Overview
9.4.1.7.4. Business Strategies and Development
9.4.1.8. Mayo Clinic
9.4.1.8.1. Company Overview
9.4.1.8.2. Product Portfolio
9.4.1.8.3. Financial Overview
9.4.1.8.4. Business Strategies and Development
9.4.1.9. MDxHealth
9.4.1.9.1. Company Overview
9.4.1.9.2. Product Portfolio
9.4.1.9.3. Financial Overview
9.4.1.9.4. Business Strategies and Development
9.4.1.10. Roche Diagnostics
9.4.1.10.1. Company Overview
9.4.1.10.2. Product Portfolio
9.4.1.10.3. Financial Overview
9.4.1.10.4. Business Strategies and Development
9.4.1.11. Rosetta Genomics
9.4.1.11.1. Company Overview
9.4.1.11.2. Product Portfolio
9.4.1.11.3. Financial Overview
9.4.1.11.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Methodology

LOADING...

Driving Factors for the Prostate Cancer Screening Market:

Challenges and Restraints:

Regional Insights:

Key Players:

Prostate Cancer Screening Market: Segmentation:

Various Tests:

o Prostate-Specific Antigen (PSA) Blood Test:

o Bone scan:

o Computed tomography (CT) scan:

o Lymph node biopsy:

o Positron Emission Tomography:

o Fine-Needle Aspiration:

End User Industry:

Table of Contents

Methodology

Related Topics

Related Reports

Breast Cancer Screening Tests Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Colorectal Cancer Screening Market Analysis & Forecast to 2024-2034

Global Breast Cancer Screening Market, By Test Type; By End User-Estimation & Forecast, 2017-2030

Global Lung Cancer Screening Software Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Breast Cancer Screening Tests Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type